Natural Psilocybin2023-01-10T07:03:16+02:00

Informed by nature
and guided by science

Informed
by nature

and guided
by science

Pioneering the use of natural psychedelics for mental health

We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.

Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.

We develop natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment.

We operate one of the first federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world.

Our range of functional mushroom wellness products harness the power of adaptogens – non-toxic, non-psychoactive plants used in ancient medicine for their stress relieving and general wellness benefits.

Bringing together leaders in the business of medicine and science

Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.

Our News

Our Global Footprint

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and quoted on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions.

Our Global Footprint

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and quoted on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions.

Our News

  • Newcourt to Acquire Psyence’s Clinical Trials Division

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

January 10, 2023|

Psyence & Newcourt have entered into a definitive business combination agreement (the “Business Combination Agreement”) on January 9, 2023 with Psyence Biomed Corp (“Psyence Biomed”), a wholly owned subsidiary of Psyence, to create a public company (the “Combined Company”) leveraging natural psilocybin in the treatment of palliative care (the “Business Combination”). Psyence Biomed is Psyence’s clinical trial division.

Go to Top